Baolingbao Biology Co Ltd Total Assets
Baolingbao Biology Co Ltd total assets. Based on the latest financial reports, Baolingbao Biology Co Ltd (002286) holds total assets worth CN¥2.93 Billion CNY (≈ $428.50 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 002286 stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Baolingbao Biology Co Ltd (2006–2025)
Total assets of Baolingbao Biology Co Ltd from 2006 to 2025. This chart illustrates how Baolingbao Biology Co Ltd's total assets have evolved over time, based on quarterly financial data. See 002286 live share price for real-time trading data and today's change.
Baolingbao Biology Co Ltd - Asset Composition Analysis
Baolingbao Biology Co Ltd Total Assets Breakdown (December 2025)
Baolingbao Biology Co Ltd total assets breakdown as of December 2025. Baolingbao Biology Co Ltd's total assets of CN¥2.93 Billion consist of 32.9% current assets and 67.1% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 9.9% |
| Accounts Receivable | CN¥267.62 Million | 9.6% |
| Inventory | CN¥321.91 Million | 11.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥114.11 Million | 4.1% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2006–2025)
This chart illustrates how Baolingbao Biology Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Baolingbao Biology Co Ltd working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Baolingbao Biology Co Ltd's current assets represent 32.9% of total assets in 2025, a decrease from 50.2% in 2006.
- Cash Position: Cash and equivalents constituted 9.9% of total assets in 2025, down from 23.7% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 11.0% in 2006.
- Asset Diversification: The largest asset category is inventory at 11.6% of total assets.
Baolingbao Biology Co Ltd Competitors by Total Assets
Key competitors of Baolingbao Biology Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $752.18 Million |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
|
China | CN¥7.88 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩739.91 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Hyundai Bioscience Co. Ltd
KQ:048410
|
Korea | ₩131.31 Billion |
|
AbClon Inc
KQ:174900
|
Korea | ₩64.50 Billion |
|
Tetratherix Ltd
AU:TTX
|
Australia | AU$38.06 Million |
Baolingbao Biology Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.79 | 1.52 | 1.06 |
| Quick Ratio | 1.22 | 0.99 | 0.78 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥450.98 Million | CN¥315.68 Million | CN¥73.68 Million |
Baolingbao Biology Co Ltd - Advanced Valuation Insights
This section examines the relationship between Baolingbao Biology Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.34 |
| Latest Market Cap to Assets Ratio | 0.18 |
| Asset Growth Rate (YoY) | 4.0% |
| Total Assets | CN¥2.78 Billion |
| Market Capitalization | $489.30 Million USD |
Valuation Analysis
Below Book Valuation: The market values Baolingbao Biology Co Ltd's assets below their book value (0.18x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Baolingbao Biology Co Ltd's assets grew by 4.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Baolingbao Biology Co Ltd (2006–2025)
The table below shows the annual total assets of Baolingbao Biology Co Ltd from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.78 Billion ≈ $407.01 Million |
+4.02% |
| 2024-12-31 | CN¥2.67 Billion ≈ $391.29 Million |
+0.57% |
| 2023-12-31 | CN¥2.66 Billion ≈ $389.08 Million |
-11.55% |
| 2022-12-31 | CN¥3.01 Billion ≈ $439.89 Million |
-0.75% |
| 2021-12-31 | CN¥3.03 Billion ≈ $443.24 Million |
+15.80% |
| 2020-12-31 | CN¥2.62 Billion ≈ $382.76 Million |
+3.85% |
| 2019-12-31 | CN¥2.52 Billion ≈ $368.57 Million |
-2.35% |
| 2018-12-31 | CN¥2.58 Billion ≈ $377.43 Million |
+22.42% |
| 2017-12-31 | CN¥2.11 Billion ≈ $308.31 Million |
+9.08% |
| 2016-12-31 | CN¥1.93 Billion ≈ $282.65 Million |
+0.94% |
| 2015-12-31 | CN¥1.91 Billion ≈ $280.01 Million |
+8.35% |
| 2014-12-31 | CN¥1.77 Billion ≈ $258.44 Million |
+5.36% |
| 2013-12-31 | CN¥1.68 Billion ≈ $245.28 Million |
+50.63% |
| 2012-12-31 | CN¥1.11 Billion ≈ $162.83 Million |
+0.02% |
| 2011-12-31 | CN¥1.11 Billion ≈ $162.81 Million |
+7.75% |
| 2010-12-31 | CN¥1.03 Billion ≈ $151.10 Million |
-4.75% |
| 2009-12-31 | CN¥1.08 Billion ≈ $158.64 Million |
+45.73% |
| 2008-12-31 | CN¥743.91 Million ≈ $108.86 Million |
+23.59% |
| 2007-12-31 | CN¥601.90 Million ≈ $88.08 Million |
+18.50% |
| 2006-12-31 | CN¥507.93 Million ≈ $74.33 Million |
-- |
About Baolingbao Biology Co Ltd
Baolingbao Biology Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of functional sugar in China and internationally. The company offers prebiotics, including galacto-oligosaccharides, isomaltooligosaccharides, fructooligosaccharides, and xylooligosaccharides; sugar alcohols and sources, such as erythritol, trehalose, crystallized fructose, a… Read more